Studies have shown that decreasing SERCA3 expression—achieved by administering nifetepimine, a dihydropyrimidone—protects lymphocytes against tumor-induced apoptosis, suggesting its potential as an immuno-restoring agent for cancer patients [103]. Here, ATP2A3 is linked to neoplasm.